Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA3 | P07451 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA6 | P23280 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790076 | 0.92 | NFKB1 (0.30) | NFKB1 | |
| SCHEMBL16420274 | 0.87 | RAB9A (0.33) | LMNA | |
| SCHEMBL31725737 | 0.84 | RAB9A (0.38) | — | |
| SCHEMBL104243 | 0.81 | — | — | |
| SCHEMBL20639270 | 0.81 | — | — | |
| SCHEMBL2121918 | 0.77 | PTPN7 (0.40) | TSHRBLMMEN1KMT2AALDH1A1 | |
| SCHEMBL3796995 | 0.75 | PTPN7 (0.43) | TSHRBLMMEN1KMT2AALDH1A1 | |
| SCHEMBL9769619 | 0.75 | — | — | |
| SCHEMBL2152346 | 0.75 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL5865499 | 0.75 | PTPN7 (0.43) | TSHRBLMMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921328-B2 | E-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130331350-A1 | E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| WO-2012037034-A1 | E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331350-A1 | E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | NFKB1 2385/4885DNM1 2493/4885CA12 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.